Source comparison
Thymosin Alpha-1 Peptide: Clinical Applications Comparison
Chronic Hepatitis B/C Enhances Th1 cytokine production (IFN-gamma, IL-2), increases CD4+ and CD8+ T-cell counts, improves viral clearance when combined with antivirals 1.6mg subcutaneous twice weekly for 24–48 weeks Meta-analysis of 14 RCTs (N=1,342) showed 26
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B/C
- Enhances Th1 cytokine production (IFN-gamma, IL-2), increases CD4+ and CD8+ T-cell counts, improves viral clearance when combined with antivirals
- 1.6mg subcutaneous twice weekly for 24–48 weeks
- Meta-analysis of 14 RCTs (N=1,342) showed 26% improvement in sustained virologic response vs controls
- Most robust evidence base—thymosin alpha-1 peptide is approved as adjuvant therapy in China, South Korea, and several EU countries for chronic viral hepatitis
- Cancer Immunotherapy Adjuvant
- Upregulates MHC class I/II expression on tumor cells, enhances dendritic cell antigen presentation, increases tumor-infiltrating lymphocytes
- 1.6–6.4mg subcutaneous 2–3× weekly during chemotherapy or checkpoint inhibitor treatment
- Phase II/III trials in lung cancer, melanoma, hepatocellular carcinoma show 15–30% improvement in 1-year survival when added to standard therapy
- Promising but heterogeneous data—most effective in combination with checkpoint inhibitors (anti-PD-1/PD-L1) rather than as monotherapy
- Vaccine Response Enhancement
- Increases antibody titers and T-cell memory formation following vaccination, particularly in immunocompromised or elderly populations
- 1.6mg subcutaneous administered on days 0, 3, and 7 surrounding vaccine dose
- RCT in elderly subjects (N=68) showed 2.4× higher anti-influenza antibody titers at 4 weeks vs placebo group
- Limited but consistent evidence—most studied with influenza and hepatitis B vaccines in populations with poor baseline immune response
- Sepsis and Severe Infection
- Reduces cytokine storm by balancing pro-inflammatory (TNF-alpha, IL-6) and anti-inflammatory (IL-10) responses, lowers 28-day mortality
- 1.6mg IV or subcutaneous every 12 hours for 5–7 days in ICU setting
- Meta-analysis of 9 trials (N=826) in sepsis showed 18% relative risk reduction in 28-day mortality
- Moderate-quality evidence—most effective when initiated within 24 hours of sepsis diagnosis, less effective in late-stage multi-organ failure